CPhI & P-MEC India – organised by UBM – is set to open its doors to more than 40,000 attendees from 120+ countries and 1500 exhibitors, as new analysis shows a massive improvement in India’s global reputation.

Sun Pharmaceutical Industries, through one of its wholly owned subsidiaries, is set to acquire Pola Pharma, a Japanese pharmaceutical company engaged in research and development, manufacture, sale and distribution of branded and generic products.

The Confederation of Indian Industry (CII) & Sathguru Management Consultants released a position paper on Indian Biosimilars Industry.

In an all-time record year for FDA approvals (48 so far in 2018), Pharmapack Europe reports that innovation is also accelerating across the drug delivery and packaging industries.

The Wasdell Group , a leading outsourcing partner for the pharmaceutical, medical device and clinical development and manufacturing industries, has experienced over 40% revenue growth in the last 24 months, following an increase in demand for its clinical trial, manufacturing and packing services.

Bormioli Pharma S.p.A. announced that Corning Pharmaceutical Glass S.p.A., a wholly-owned subsidiary of Corning Incorporated, and Bormioli Pharma entered into a binding agreement for the sale of Bormioli Pharma’s pharmaceutical glass tubing business to Corning.

Following Galderma-Spirig’s decision to close their Egerkingen site in September 2017, Omya International, based in neighboring Oftringen, will move research and development activities to the site. To this end, Omya is acquiring the property from Galderma-Spirig’s parent company, Nestlé Skin Health.

Bio capacity in Europe is predicted to overtake the USA by 2020 according to the bio findings of CPhI Annual Report released live at bioLIVE in Madrid (9-11, October 2018) – adjacent to CPhI Worldwide.

The global ADC therapeutics market is expected to grow to $4bn by 2023, with double digit approvals within 3-years, according to a new analysis in the CPhI Annual Report – the complete findings of which were released live at CPhI Worldwide in Madrid (9-11, October 2018).

CPhI Worldwide, the world’s largest pharma event – taking place in Madrid (9-11, October 2018) and organized by UBM (part of Informa plc) – releases its annual report analysis of opioid contract services and continuous manufacturing.

CPhI Worldwide the world’s largest pharma event – taking place in Madrid October (9-11) and organized by UBM (part of Informa plc) – releases the first part of its 6th Annual Report with a stark warning from Girish Malhotra, President of EPCOT International, that regulators are holding back the industry’s ability to innovate.

CPhI MEA (Middle East and Africa) launches next month as favourable market conditions are driving increased growth across the Middle East and North Africa (MENA) pharma market – ageing and gentrifying populations, increased healthcare spending, and a modernising supply chain are transforming prospects in the region.

Genstar Capital, a leading investor in healthcare technology and services companies,is pleased to announce the acquisition of CRF Health, a global provider of eCOA and eConsent solutions for the life sciences industry.

Sovereign Capital Partners, the UK private equity Buy & Build specialist, is pleased to announce the realisation of its investment in Xendo - a leading independent consultancy and project management organisation in the fields of (bio)pharmaceutical products, medical devices and healthcare - to ProPharma Group, a portfolio company of US-based Linden Capital Partners.

The Korean pharma market is experiencing significant growth in finished drug products, according to CPhI Korea. Over the last 12 months, market conditions have spurred a strong expansion in exports of finished formulations, driven primarily by an expanding domestic generics market.

Recipharm and Sanofi announced that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm.

Leading Asia Pacific CRO Novotech commended the Turnbull Government's Federal Budget decision to exclude clinical trials activity from a A$4m cap on cash refunds, or any lifetime cap on refunds.

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced financial and company results for the first quarter of 2018.

Novartis AG announced that it has completed the acquisition of AveXis, Inc. through the consummation of a merger of its indirect wholly-owned subsidiary, Novartis AM Merger Corp, with and into AveXis without a vote of the AveXis stockholders in accordance with Section 251(h) of the Delaware General Corporation Law.

Eli Lilly and Company announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly.

Contract development and manufacturing organisation (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.

Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has more than doubled its sales in the US over the last two years.

MIMETAS, leader in organ-on-a-chip products and tissue models, has secured 20.5 million USD in financing from an international syndicate from Asia and Europe.


TraceLink’s Global Drug Supply, Safety and Traceability Report
survey highlights a lack of industry readiness for U.S. DSCSA, and
concerns in European nations on readiness for the February 2019
EU FMD compliance deadline
Organization Breakdown*
Hospitals n=195
Pharmaceutical companies n=174
Contract Manufacturing Organizations (CMOs) n=155
Pharmacies n=81
Wholesale Distributors n=50
Third Party Logistic Companies n=11
*all with compliance regulations for either the Food and Drug
Administration’s (FDA) Drug Supply Chain Security Act (DSCSA) and/or the
European Union’s Falsified Medicines Directive (FMD)
U.S. Serialization Readiness:
Industry Belief vs. Reality
of pharma
they are
very ready
actually ready
not one
for serialization
based on
pharma company is
necessary steps
ONLY 11%
of pharma companies
feel that their CMOs
were ready to ship
serialized products
CMOs that feel
Utmost Concern:
very ready
for serialization
98% of CMOs had concerns that equipment
shortages will affect customer compliance
EU Serialization Readiness:
Industry Belief vs. Reality
of pharma
companies feel
very ready
for serialization
ONLY 15%
EU pharma companies
of EU pharma
believe they will be
companies and
sending serial numbers
CMOs are truly
to the EU Hub in time for
on target for
the February 2019
EU pharma company is
integrated with the
majority of their CMOs
Hidden Values Behind
Serialized Data
Majority of respondents
and secure
see added value in
and recall
serialized data
Better business
relationships up and
down the drug
supply chain
Networked ecosystems of trading partners
stand to achieve the most significant ROI
from serialization data

To view the entire report visit:

Takeda Pharmaceutical Company Limited notes the share price movement with respect to Shire plc.

  • Sales up 25.5 percent to EUR 9.66 billion in fiscal year 2017
  • Strong volume increase in all segments

TxCell SA , a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, announces its financial results for 2017 and its objectives for 2018.

Contract development and manufacturing organisation (CDMO) Ardena has acquired ChemConnection, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and nanomedicines.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported.

Why Roche paid $1.9 billion for a 5-year-old company
Earlier this month, Roche, a global pharmaceutical giant, acquired Flatiron Health, an oncology-focused electronic health records (EHR) company, for $1.9 billion. Prior to this, Roche had a 12.6% stake in the company, and it decided to increase the stake by completely acquiring the business.

Period October – December 2017

  • Revenues amounted to SEK 0.0 (0.3) million
  • Operating result amounted to SEK –22.6 (–16.4) million
  • Result after tax amounted to SEK –22.4 (–16.3) million,corresponding to SEK –0.36 per share (–0.27) before and after dilution
  • Cash flow from operating activities amounted to SEK –14.1 (–8.3) million

Capio has signed an agreement to acquire 100% of Novakliniken with operations in the southeastern parts of Skåne, Sweden. Novakliniken operates eight primary care centers and two branches, and provides some occupational health and dental services.

Reckitt Benckiser Group PLC is attempting to buy Pfizer Inc’s consumer healthcare business and analysts at JP Morgan think a potential deal makes sense.

Merck , known as MSD outside the USA and Canada, and Viralytics Limited announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics, an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers by way of a scheme of arrangement (Scheme) for AUD 1.75 cash per Viralytics share.

Swiss pharmaceutical giant Roche Group is buying Flatiron Health, an Alphabet-backed cancer-focused start-up founded by two former Google employees, according to sources familiar with the matter.

Nuvo Pharmaceuticals Inc.™ , a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) Limited (Nuvo Ireland) has acquired the U.S. rights to Resultz® (50% isopropyl myristate, 50% cyclomethicone D5 topical solution  lice and egg removal kit) from Piedmont Pharmaceuticals LLC (Piedmont). 

Recipharm, a leading CDMO , has received recognition for its commitment to its French operations. The award “le Prix d’Excellence 2017 - Spécial Sciences de la vie” is presented by the Swedish Chamber of Commerce in France.

Celonic AG, a leading global biologics development and manufacturing services provider, and Glycotope, a clinical stage immune-oncology company, today announced the successful completion of Celonic’s acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany.

Atomo Diagnostics, a world leader in innovative point-of-care, rapid diagnostic devices, announced today that its Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body.

PCI Pharma Services is pleased to announce the acquisition of pharmaceutical and healthcare contract packaging services provider Millmount Healthcare, located near Dublin, Ireland.

On October 18th, the Marchesini Group, alongside SEA Vision - the Group’s longstanding Italian partner for vision systems for pharmaceutical and OEM industries - will be at the International Conference Industry 4.0: Trends in Pharma Manufacturing, Technologies & Packaging.

Gilead Sciences, Inc. and Kite Pharma, Inc announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash.

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the second quarter of 2017.

TraceLink Inc., the world’s largest track and trace network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that it has acquired ROC IT Solutions, the leader in intelligent edge data capture for serialized product inventory in the pharmaceutical supply chain.

Valeant Pharmaceuticals International, Inc announced that certain affiliates of the Company have entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited .

Medicure Inc , a leading Canadian specialty pharmaceutical company, is pleased to announce that it has closed the acquisition of additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders as previously announced on July 10, 2017.

Valeant Pharmaceuticals International, Inc. announced that its affiliate has completed the sale of all of the outstanding equity interests in its former subsidiary Dendreon Pharmaceuticals LLC to the Sanpower Group, Co., Ltd. , for $819.9 million in cash.

Imprimis Pharmaceuticals, Inc , an ophthalmology-focused pharmaceutical company, announced it has entered into an agreement to sell its Folcroft, Pennsylvania facility and sinus related assets for $450,000.  

Eurofins Scientific , a world leader in biopharmaceutical testing, announces the acquisition of Alphora Research Inc , a full service contract research, development and manufacturing organization (CRDMO) for complex and niche small molecule active pharmaceutical ingredients (APIs), based in Mississauga, Ontario, Canada.    

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced financial and company results for the first quarter of 2017. 

A global life science technology firm has surpassed the €20 million milestone for sales of its manufacturing execution system (MES) services.

Imprimis Pharmaceuticals Inc , an ophthalmology-focused pharmaceutical company, announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity, an innovative and patented ophthalmic topical solution and gel technology for patients with dry eye disease (DED).  

Thermo Fisher Scientific Inc, the world leader in serving science announced that it has acquired Core Informatics, which provides a leading cloud-based platform supporting scientific data management.

Takeda Pharmaceutical Company Limited announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc for $24.00 per share in cash.

Thermo Fisher Scientific Inc, the world leader in serving science completed its previously announced acquisition of Finesse Solutions, Inc., a leader in the development of scalable control automation systems and software for bioproduction.

Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally.

Quality Packaging Specialists International, LLC (QPSI) has acquired 100% ownership of International Labs, LLC (INL) in an equity exchange transaction.

Mallinckrodt plc , a leading specialty pharmaceutical company, announced today that it has closed the sale of its global Nuclear Imaging business to IBA Molecular (IBAM) for approximately $690 million before tax, including up-front and contingent considerations and the assumption of long-term obligations.

WestRock Company and Multi Packaging Solutions International Limited announced that a definitive agreement has been reached for WestRock to acquire all of the outstanding shares of MPS for $18.00 per share in cash and the assumption of an estimated $873 million in net debt, for a total enterprise value of $2.28 billion.

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).

Moberg Pharma AB has now completed the acquisition of DermoPlast® Prestige Brands, Inc. in accordance with the terms announced on December 6. The purchase price was 47.6 million plus inventory value.

OncoGenex Pharmaceuticals, Inc , a publicly held oncology biopharmaceutical company, and Achieve Life Science, Inc , a privately held specialty pharmaceutical company, announced that they have entered into a definitive merger agreement under which OncoGenex will acquire Achieve in an all-stock transaction.

Factor One Source Pharmacy and Fast Access Specialty Therapeutics announced today that they have entered into a definitive agreement under which FOSRx will acquire F.A.S.T. for a combination of cash and stock.

Eli Lilly and Company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).

CSL Limited -At the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana, held on 15 November 2016, CSL Behring announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy.

GlaxoSmithKline plc announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD).

Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) in patients with or without hydroxyurea therapy[1].

Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region.

Cumberland Pharmaceuticals , a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line.

Sorrento Therapeutics, Inc. Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for treatment of cancer.

Novartis announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.

Catalent Inc the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced that it has agreed to acquire Accucaps Industries Limited (Accucaps).

Arrow Generiques SAS, the French subsidiary of Aurobindo Pharma Ltd announced the signing of an agreement to acquire select commercial products in France from Teva.

Aegerion Pharmaceuticals Inc and QLT Inc announced the completion of their merger transaction, as a result of which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name to Novelion Therapeutics Inc.

Aralez Pharmaceuticals Inc a global specialty pharmaceutical company announced that its subsidiary, Aralez Pharmaceuticals Trading DAC (Aralez Ireland), has completed its acquisition of the U.S. rights to Toprol-XL® (metoprolol succinate) and its Authorized Generic (AG) from AstraZeneca.

Lexicon Pharmaceuticals Inc announced that it has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb Company as part of their neuroscience drug discovery alliance.  

Medivir AB announces that it has entered into an agreement to acquire two clinical stage oncology programs from Tetralogic Pharmaceuticals Corporation , advancing and expanding its clinical pipeline.

Teva Pharmaceutical Industries Ltd announced that it has completed its acquisition of Anda, Inc., a leading distributor of generic pharmaceuticals in the U.S., from Allergan plc.

Quintiles IMS Holdings has successfully completed its merger of equals transaction between IMS Health Holdings and Quintiles Transnational Holdings.

ICU Medical will acquire all of Pfizer’s global infusion therapy business, Hospira Infusion Systems (HIS), for $1 billion in cash and stock.

GlaxoSmithKline has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 300 per share (the "Placing Shares"), raising gross proceeds of approximately ZAR 8,470 million.

PAREXEL International Corporation , a leading global biopharmaceutical services provider announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc , a leading, global functional service provider (FSP) serving the biopharmaceutical industry.

Pfizer Inc announced the successful completion of its acquisition of Medivation, Inc . As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for $81.50 per share in cash, without interest, subject to any required withholding of taxes.

Teva Pharmaceutical Industries Ltd announced that it has completed its acquisition of Anda, Inc., a leading distributor of generic pharmaceuticals in the U.S., from Allergan plc.

In announcing the result, Amcor’s Managing Director & CEO, Mr Ron Delia said: “, Amcor reported a strong full year result with growth in earnings, returns and cash flow delivered in a challenging macroeconomic environment.

Sonoco ThermoSafe has acquired the PharmaPort 360™ assets, licenses, trademarks and manufacturing rights from AAR, to enter the active temperature-controlled cargo containers market.

The global rigid film producer Klöckner Pentaplast will acquire Farmamak Review from Venture Capital Investment Trust Inc. (Review Initiative). Farmamak will operat on as a subsidiary within the Klöckner Pentaplast Group. 

Ball Corporation published its fifth biennial sustainability report, which details the company's progress toward its updated priorities – product stewardship, operational excellence, talent management and community ambassadors – and sets a clear path for the future with 10 new ambitious goals to be achieved by 2020.

Pfizer Inc announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States.

Momenta Pharmaceuticals, Inc reported its financial results for the second quarter ended June 30, 2016.For the second quarter of 2016, the Company reported total revenues of $26.4 million, including $20.7 million in product revenues from Sandoz's sale of Glatopa® (glatiramer acetate injection).

Boehringer Ingelheim reported currency-adjusted growth in all its core businesses in the first half of 2016. At the same time, the research-driven pharmaceutical company achieved key strategic milestones by signing contracts to exchange businesses with Sanofi and completing the internal restructuring of its human pharmaceuticals business. For the current year, Boehringer Ingelheim is still expecting a slight year-on-year increase in currency-adjusted net sales. 

• Half-year net sales of approximately 7.3 billion euro
• Currency-adjusted net sales growth of 2%
• Key strategic milestones achieved

In the first half of 2016, Boehringer Ingelheim generated total net sales of approximately 7.3 billion euros, which after currency adjustment represents an increase of 2% compared with the same period last year (-1% in euro terms). Excluding the US generics business Roxane, which was sold in February, currency-adjusted growth in the first six months of the financial year amounted to as much as 5% (+1% in euro terms). 

Product launches drive growth
Prescription medicines, Boehringer Ingelheim’s biggest business, achieved net sales of 5.45 billion euros in the first half of the year. This represents a currency-adjusted increase of 4% (+1% in euro terms). As in prior years, the respiratory medicine SPIRIVA® for the treatment of COPD and asthma was the top-selling medicine, despite its patent expiring in some markets. Boehringer Ingelheim generated net sales of some 1.46 billion euros with the product, which represented a currency-adjusted decline of 16%, as expected (-17% in euro terms). 

This effect was, however, more than offset by the very gratifying net sales performance of new medicines. The diabetes portfolio was an important growth driver in the first half of the year, with an increase of 55% after currency adjustment to 760 million euros (+53% in euro terms). A positive development from a medical perspective was new data on JARDIANCE® (empagliflozin) in the treatment of type 2 diabetes: it demonstrated that, when taken in addition to the standard treatment, the medicine reduced the risk of a reoccurrence or a deterioration of renal disease in patients with type 2 diabetes and existing cardiovascular disease by 39% compared to the placebo. Empagliflozin is thus the only SGLT2 inhibitor that could slow the progression of renal disease in people with type 2 diabetes and cardiovascular disease in a cardiovascular outcome study. 

Strong growth was also reported for OFEV® for treating idiopathic pulmonary fibrosis (IPF) – net sales were up by 166% to 250 million euros (+166% in euro terms). With its anticoagulant PRADAXA® Boehringer Ingelheim generated net sales of 650 million euros corresponding to a currency-adjusted increase of 6% (+4% in euro terms).

Net sales of over-the-counter medicines rose by 5% on a currency-adjusted basis in the reporting period to 750 million euros (-4% in euro terms). That amounts to over 10% of total net sales. International core brands are DULCOLAX®, BUSCOPAN®, PHARMATON®, MUCOSOLVAN® and BISOLVON®. 

In the animal health business, Boehringer Ingelheim achieved currency-adjusted growth of 6% in the first half of 2016, amounting to 688 million euros (+4% in euro terms). This corresponds to 9.5% of total net sales. 

The biopharmaceuticals business, in which Boehringer Ingelheim is exclusively involved in contract manufacturing for third parties, grew slightly by 1% to 216 million euros. In the coming years, 

Boehringer Ingelheim is planning to invest more than 0.5 billion euros in biopharmaceutical production at its site in Vienna, Austria.

Boehringer Ingelheim

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.For more information please visit


Group sales increase by 2.3 percent (Fx & portfolio adj.) to EUR 11,833 million / Pharmaceuticals continues strong growth trend / Consumer Health increases sales / Crop Science business holds steady in a continuingly difficult market environment / EBITDA before special items up 5.7 percent to EUR 3,054 million / Net income improves by 18.6 percent to EUR 1,380 million / Core earnings per share increase by 4.0 percent to EUR 2.07 / Group forecast raised.

Gilead Sciences, Inc  announced that its second quarter 2016 financial results will be released on Monday, July 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2016 and provide a general business update.

GSK delivers further progress against strategy with strong Q2 performance

Group sales £6.5 billion, +4% CER, with growth across all three businesses

Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2016 of $0.80 per share on the company’s common stock. The dividend is payable on September 6, 2016 to shareholders of record at the close of business on August 23, 2016. The ex-dividend date is August 19, 2016. 

Johnson & Johnson announced that Johnson & Johnson Consumer Inc. has successfully completed the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal care products, for $3.3 billion in cash.

Merck known as MSD outside the United States and Canada announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the fourth quarter of 2016. Payment will be made on Oct. 7, 2016 to shareholders of record at the close of business on Sept. 15, 2016.

Pfizer Inc announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system.

Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 before the US financial markets open.

Show more
Show less
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok